SLBT — SL Science Holding Ltd
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2070534 ·
Taiwan
Last close
$0.64
Market Cap
$356.14M
52W High
$14.50
52W Low
$0.62
ADV30
52,678
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 8,911,138 | 8,306,692 | 1,940,448 |
| Dec 2025 | — | — | — | — | 2,817,180 | 1,258,616 | 533,277 |
| Jun 2025 | — | — | — | — | 5,791,578 | 3,373,292 | 1,061,102 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-7,646,583
Inventory
$73,267
Receivables
$164,285
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,270,101
EBITDA
$-2,284,772
Free Cash Flow
$372,344
Enterprise Value
$4,502,877
Total Cash
$3,373,292
Total Debt
$305,669
Shares Out
560,759,757
Trailing EPS
$-0.01
Book Value
$1.29
ROE
-25.6%
ROA
-14.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,197,249 | -3,837,488 | -3,819,818 | 2,817,180 | 533,277 | 2,283,903 | -1,909,796 |
| Dec 2024 | 3,363,603 | -1,196,111 | -1,191,333 | 5,931,952 | 204,899 | 5,727,053 | 280,158 |
| Dec 2023 | 878,971 | 96,828 | 399,035 | 4,241,910 | 668,066 | 3,573,844 | -2,454,261 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JSPR | Jasper Therapeutics, Inc. | $344.06M | $10.34 | — |
| ALEC | Alector, Inc. | $381.13M | $2.56 | — |
| CCCC | C4 Therapeutics, Inc. | $332.23M | $2.53 | — |
| TECX | Tectonic Therapeutic, Inc. | $392.55M | $20.08 | — |
| XFOR | X4 Pharmaceuticals, Inc | $315.53M | $3.09 | — |
News headlines (Yahoo Finance, 1h cache)
SL Science Holding Limited Reports First Half 2026 Financial Results
2026-10-26 20:15 · Yahoo
SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma
2026-09-24 12:00 · Yahoo
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
2026-08-27 12:00 · Yahoo
SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall
2026-08-18 17:13 · Yahoo
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma
2026-08-11 12:00 · Yahoo
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
2026-07-17 12:00 · Yahoo
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
2026-07-10 12:00 · Yahoo
Top Midday Decliners
2026-06-22 18:06 · Yahoo
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
2026-09-02 20:10 · Yahoo
SL Science Holding Limited Reports Full Year 2025 Financial Results
2026-06-18 21:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.